NZOZ Innowacyjna Medycyna Read-Gene S.A.
- Address
- Alabastrowa 8, 72-003 Grzepnica, Poland
NZOZ Innowacyjna Medycyna Read-Gene S.A.
NZOZ Innowacyjna Medycyna Read-Gene S.A. is a specialized clinical research center focused on innovative oncology treatments, with particular expertise in BRCA-mutated cancers. The center plays a crucial role in long-term patient care through roll-over studies, ensuring continuity of treatment for patients who benefit from targeted cancer therapies.
- BRCA-mutated ovarian and breast cancer research
- Platinum-sensitive relapsed ovarian cancer studies
- BRCA-mutated pancreatic, prostate, and endometrial cancer trials
The center specializes in extended access programs that monitor long-term safety and tolerability of oncology treatments, particularly focusing on PARP inhibitor therapy across multiple solid tumor types. Their comprehensive approach encompasses various epithelial ovarian cancers and metastatic cancers with genetic mutations, providing patients with continued access to promising therapeutic options beyond initial trial completion.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in NZOZ Innowacyjna Medycyna Read-Gene S.A.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Randomized, Double-Blind, Placebo-Controlled Phase III Study of Olaparib Maintenance Monotherapy in BRCA-Mutated Advanced Ovarian Cancer Post-Platinum Chemotherapy | AstraZeneca AB | Phase III | Not Recruiting | Sep 2013 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Olaparib | 1 | Unknown | 2013-09-06 | 2013-09-06 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.